Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...

The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...

Roche (RHHBY) announced that it will present new data at the Muscular Dystrophy Association, MDA conference, 16-19 March, 2025, in Dallas, ...

Elevidys has been developed by Sarepta in partnership with pharma giant Roche RHHBY. SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Roche has ...

Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference: Basel Tuesday, March 18, 2025, 11:00 Hrs [IST] ...

In a statement, the Cambridge, Massachusetts-based biotech said that a young man with DMD died after receiving Elevidys, a gene therapy the company markets with Roche (OTCQX:RHHBY) under a 2019 ...